Literature DB >> 21419854

Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.

Kenny J Watson1, William P Gorczyca, John Umland, Ying Zhang, Xian Chen, Sunny Z Sun, Bernard Fermini, Mark Holbrook, Piet H Van Der Graaf.   

Abstract

INTRODUCTION: Delayed ventricular repolarisation is manifested electrocardiographically in a prolongation of the QT interval. Such prolongation can lead to potentially fatal Torsades de Pointes. Moxifloxacin is a fluoroquinolone antibiotic which has been associated with QT prolongation and, as a result, is recommended by the regulatory authorities as a positive control in thorough QT studies performed to evaluate the potential of new chemical entities to induce QT prolongation in humans. The sensitivity of the cynomolgus monkey as a quantitative preclinical predictor of the PK-QTc relationship is discussed.
METHODS: Cardiovascular monitoring was performed in the telemetered cynomolgus monkey for 22 h following oral administration of Moxifloxacin (10, 30 and 90 mg/kg) or placebo. QTc was derived using an individual animal correction factor (ICAF): RR-I = QT-I--(RR-550)* (IACF). A PKPD analysis was performed to quantify the increase in placebo-adjusted QTc) elicited by administration of Moxifloxacin. In addition, the rate of onset of hERG channel blockade of Moxifloxacin was compared to Dofetilide by whole cell patch clamp technique in HEK-293 cells stably expressing the hERG channels.
RESULTS: Moxifloxacin induced a dose dependent increase in QTc). A maximum increase of 28 ms was observed following administration of 90 mg/kg Moxifloxacin. The corresponding maximum free systemic exposure was 18μM. Interrogation of the PK-QTc relationship indicated a direct relationship between the systemic exposure of Moxifloxacin and increased QTc. A linear PKPD model was found to describe this relationship whereby a 1.5 ms increase in QTc was observed for every 1 μM increase in free systemic exposure. DISCUSSION: The exposure dependent increases in QTc observed following oral administration of Moxifloxacin to the cynomolgus monkey are in close agreement with those previously reported in human subjects. A direct effect linear relationship was found to be conserved in both species. As a result of the quantitative agreement in both species, the utility of the telemetered cynomolgus monkey as a preclinical predictor of QTc) prolongation is exemplified. Furthermore, the rate of onset of hERG channel blockade observed in patch clamp offers a mechanistic insight into the relative rates of channel blockade observed in vivo with both Moxifloxacin and Dofetilide.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419854     DOI: 10.1016/j.vascn.2011.03.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  12 in total

1.  A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Authors:  S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-07       Impact factor: 2.745

2.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens.

Authors:  Tutik Kusmiati; Ni Made Mertaniasih; Johanes Nugroho Eko Putranto; Budi Suprapti; Nadya Luthfah; Soedarsono Soedarsono; Winariani Koesoemoprodjo; Aryani Prawita Sari
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-06-06

4.  Translating QT interval prolongation from conscious dogs to humans.

Authors:  Vincent F S Dubois; Giovanni Smania; Huixin Yu; Ramona Graf; Anne S Y Chain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

5.  Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.

Authors:  V F S Dubois; E Casarotto; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2016-09-07       Impact factor: 8.739

6.  Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK Model.

Authors:  LiQin Zhu; JianWei Yang; Yuan Zhang; YongMing Wang; JianLei Zhang; YuanYuan Zhao; WeiLin Dong
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

7.  Predicting QTc Prolongation in Man From Only In Vitro Data.

Authors:  D J Leishman
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-08-20

8.  Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial.

Authors:  Wantong Zhang; Baochen Zhu; Weiyi Cao; Rui Li; Shuge Wang; Rui Gao
Journal:  Trials       Date:  2018-09-14       Impact factor: 2.279

9.  Correlation of inflammatory cytokines on corrected QT interval in rifampicin-resistant tuberculosis patients.

Authors:  Tutik Kusmiati; Ni Made Mertaniasih; Johanes Nugroho Eko Putranto; Budi Suprapti; Nadya Luthfah; Winariani Koesoemoprodjo; Aryani Prawita Sari
Journal:  Ann Med Surg (Lond)       Date:  2021-09-14

10.  Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.

Authors:  V F S Dubois; W E A de Witte; S A G Visser; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.